Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy - Wikidata - wikimedia - TriplyDB

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy

http://www.wikidata.org/entity/Q36786002

about

Polypoidal Choroidal Vasculopathy in Asians Polypoidal choroidal vasculopathy: an update on therapeutic approaches Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement.Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis.Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters.Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy.Author's response: Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy.Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy.Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy.Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy.Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

P2860

Q26799548-0EE74B12-4477-4F98-9C42-CC2C69CC809C Q27006758-DBA3DA05-9892-44EA-82F0-F5DB21D3E3B7 Q35368673-0812F0BB-365D-43DE-B752-006532DF3D27 Q35838315-247D8403-292B-43AF-BBDF-0184BA8CE961 Q36750280-99EAD4C4-B8AA-4627-AAD2-4699B703E938 Q36955686-67DE52C4-A444-49C9-AD08-F8531AD70E9F Q37095502-A3543F0C-B9EA-426E-ABE0-60CE08B2973B Q37136866-9122EC42-61AB-4578-A9A9-E70D5FA482CB Q37445392-9C641172-BA34-4DEC-AA56-26B0D3DD5F0A Q44000939-FC2B1439-A580-4EC7-AEFB-5F9631521321 Q47105965-D4B85778-6924-471A-AC30-6D97E5D3A7FE Q47338796-8AD75AC4-AE87-458E-B87D-9F13B65A1BDD Q47737603-D59CB24F-7DA4-4D82-AE73-16306EBED37A Q50227158-9BDAF542-3ECC-4A7C-8F65-4AEF0D23CE3A Q50446492-74BB607B-25DD-4B77-B8E3-D754E5B66748 Q50452433-D845F2A2-F169-4B06-BA1C-4F95C51B18F4 Q53675303-8C64FA99-BA3E-4D76-BBFD-B61313EFE795 Q54200975-3A50FAC7-EC09-4AB0-A3FF-BF3A8ED5B245 Q54309984-AB2AAE10-EE42-483E-8705-0CB386F0F2ED Q58694356-8857786B-EFC2-448E-A27F-6EF23A46ED0C

P2860

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy

http://www.wikidata.org/entity/Q36786002

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Results of 2 years of treatmen ...... ypoidal choroidal vasculopathy

@en

type

label

Results of 2 years of treatmen ...... ypoidal choroidal vasculopathy

@en

prefLabel

Results of 2 years of treatmen ...... ypoidal choroidal vasculopathy

@en

P1433

Q36786002-634DA635-CC4B-4246-9C57-A63C86F1CBB6

P1476

Q36786002-FF9B55A6-0B46-461D-AA0E-409DA8D90DD1

P2093

Q36786002-0AA7B08B-55A1-4966-BECD-F7EBAE684C3F

Q36786002-20A0AEE5-F868-405B-8122-B61308EB7146

Q36786002-398D4841-ECBA-40BF-B54C-3188D325F112

Q36786002-40EDD6A7-8D5F-4CC8-A6FC-66FF82E10C55

Q36786002-5A44CF68-B823-4852-AE19-11A26E4666C8

Q36786002-7DB9F52F-4B29-42CA-8A19-FA51C610701B

Q36786002-AF3BBC71-6A40-4B97-8FFD-8BB6BA847A3A

Q36786002-BD3B27B4-32AB-4B92-B531-E456E162784C

Q36786002-C225DCDE-7E35-460E-870F-8A8309E442D5

P2860

Q36786002-0F9A4F1E-D19B-4BA8-9C14-B1404A55E8E6

Q36786002-0FCFCEFF-FE06-4D0F-A70F-CCF5DF0C9B8C

Q36786002-14871DDB-7AFB-41BD-AA49-AB05E3B1F45E

Q36786002-1B531313-11A7-4443-9E1A-B417FE24E8DC

Q36786002-1B67478B-915A-4D58-AC58-0D82A272C3A1

Q36786002-3A50127C-2AF9-477B-AE81-50F07569911C

Q36786002-3B695A4B-4158-4CDB-915B-DB06FF320B8B

Q36786002-3F1AB979-138E-4692-AB48-AE8DF5368FA0

Q36786002-43E73993-83F8-4EC7-89E4-0C69C82AC59B

Q36786002-4F05766E-FA6E-4DF8-B858-B67CE32034F9

P304

Q36786002-F32CE6D6-74DD-4A81-85D2-1336E719BA8C

P31

Q36786002-994DAEFF-427A-457C-9229-95A7AF0146F7

P356

Q36786002-9BBF6790-D387-4FD5-8FC0-8BDDC7158E60

P407

Q36786002-7D9F2FAA-14E9-45A8-98F3-BA0629F67DAD

P433

Q36786002-32DF7363-D50A-4EC6-9BEE-58A9545A091A

P478

Q36786002-998B0CDE-F257-4C4B-904D-918A4187C8D6

P577

Q36786002-F7053EB1-8DB6-405F-AA4A-C5CF54325288

P5875

Q36786002-CC7F794B-CE27-4091-8BBD-FD348F146B95

P698

Q36786002-487CFF99-9BB4-4E2D-8638-92502A0C4C12

P932

Q36786002-2DF9960A-B41B-4107-A9CA-188BB95BFBFB

P356

BJOPHTHALMOL-2012-302652

P1433

British Journal of Ophthalmology

P1476

Results of 2 years of treatmen ...... ypoidal choroidal vasculopathy

@en

P2093

Hideo Ohtsuka

http://www.w3.org/2001/XMLSchema#string

Hirokuni Kitamei

http://www.w3.org/2001/XMLSchema#string

Kimitaka Takami

http://www.w3.org/2001/XMLSchema#string

Makoto Higuchi

http://www.w3.org/2001/XMLSchema#string

Reiko Matsushita

http://www.w3.org/2001/XMLSchema#string

Shoko Kosaka

http://www.w3.org/2001/XMLSchema#string

Shoko Shioya

http://www.w3.org/2001/XMLSchema#string

Taiichi Hikichi

http://www.w3.org/2001/XMLSchema#string

Takuro Matsushita

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.

Treatment of polypoidal choroidal vasculopathy with photodynamic therapy.

Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Polypoidal choroidal vasculopathy: a review.

Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.

Polypoidal choroidal vasculopathy: natural history.

Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

P304

617-621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJOPHTHALMOL-2012-302652

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235689636

http://www.w3.org/2001/XMLSchema#string

P698

23428984

http://www.w3.org/2001/XMLSchema#string

P932

3632979

http://www.w3.org/2001/XMLSchema#string